Abstract
BACKGROUND: Mesotherapy, a widely utilized minimally invasive cosmetic procedure, carries potential risks of adverse reactions due to non-standardized protocols and overuse. Delayed granulomatous reactions represent a chronic complication, imposing significant physical and psychological burdens on patients. OBJECTIVE: This case series aims to evaluate the efficacy and safety of tofacitinib in managing non-infectious granulomatous reactions following mesotherapy. METHODS: This retrospective analysis included six patients diagnosed with non-infectious granulomatous reactions post-mesotherapy, treated at Peking Union Medical College Hospital between October 2021 and April 2025. All patients received oral tofacitinib. Clinical outcomes, treatment regimens, and safety profiles were assessed. RESULTS: All six patients demonstrated significant improvement in skin lesion severity, with no treatment-related adverse events observed during follow-up. CONCLUSION: Oral tofacitinib exhibits promising clinical efficacy and a favorable safety profile for non-infectious granulomatous reactions induced by mesotherapy, positioning it as a viable therapeutic option during the inflammatory phase.